GLP-1 receptor agonist use does not increase insulin discontinuation with type 2 diabetes

For veterans with benignant 2 diabetes (T2D) receiving basal insulin therapy, the summation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not summation the complaint of insulin discontinuation compared with different glucose-lowering agents, according to a survey published online July 14 successful the Annals of Internal Medicine.